Marizyme adds new board members

FORT COLLINS — Marizyme Inc. (OTC: MRZM) — a company focused on acquiring, developing and commercializing late-stage drug assets for acute care use — has appointed new members to its board.

James Sapirstein and Terry Brostowin have been added to the company’s board of directors. Sapirstein, appointed executive chairman, has 35 years of success in the pharmaceutical industry. He has launched nearly two dozen pharmaceutical drugs in the fields of infectious disease and cancer. He previously worked at companies like Bristol-Myers Squibb and Hoffman-LaRoche. He has also been CEO of early-stage biotech companies.

Brostowin is an attorney admitted to the federal court in the Eastern and Southern districts of New York. His expertise is in contracts and commercial litigation.

In addition to the new directors, two existing directors have stepped down from Marizyme. Juan Francisco Gutierrez and Marco Nicolaides have resigned from the board. Gutierrez cited health reasons.

on Facebook on LinkedIn